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Abstract: Ghrelin, a 28-amino acid peptide hormone expressed in X/A-like endocrine cells of the
stomach, is the only known peripherally produced and centrally acting peptide that stimulates
food intake and therefore attracted a lot of attention with one major focus on the treatment of
conditions where an increased energy intake or body weight gain is desired. Anorexia nervosa is an
eating disorder characterized by a pronounced reduction of body weight, a disturbed body image
and hormonal alterations. Ghrelin signaling has been thoroughly investigated under conditions
of anorexia nervosa. The present review will highlight these alterations of ghrelin in anorexia and
discuss possible treatment strategies targeting ghrelin signaling. Lastly, gaps in knowledge will be
mentioned to foster future research.
Keywords: animal model; body weight; brain-gut axis; drug; eating disorder; food intake; gut-brain
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1. Introduction
Ghrelin was discovered in 1999 by Kojima and colleagues as an endogenous ligand of the growth
hormone secretagogues receptor 1a (GHSR1a) stimulating the release of growth hormone (GH) from
the pituitary [1] leading to the release of insulin-like growth factor 1 (IGF-1) [2]. Interestingly, GHSR1a
is expressed, among others, in the arcuate nucleus, colocalized in neurons expressing Agouti-related
peptide (AgRP) and neuropeptide Y (NPY) that regulate food intake [3]. Ghrelin was found to be
secreted from oxyntic glands in the gastric fundus [1] and the subsequent description of ghrelin’s
effects on food intake, glucose metabolism and body weight followed soon thereafter [4].
Ghrelin is derived from preproghrelin and activated by acylation, namely by the attachment of
a fatty acid side chain to its serine 3 residue catalyzed by the ghrelin-O-acyl transferase (GOAT) [5].
Interestingly, another peptide hormone is derived from this precursor, namely obestatin [6]. However,
since the initially proposed effects were not reproducibly by several other groups as well as by the
original authors, its role is controversially discussed [7] Therefore, we will not focus on obestatin in
the present review.
Acylated ghrelin is able to bind to and activate the GHSR1a leading to, among other effects,
a stimulation of food intake [8], reduction of insulin secretion resulting in hyperglycemia [9] and
stimulation of gastric motility [10], whereas desacyl ghrelin—long thought to represent a non-active
form of ghrelin—is assumed to counterbalance the orexigenic effect of acyl ghrelin [11,12]. It is
to note that desacyl ghrelin does not bind to the GHSR1a at physiological but acts as agonist at
supraphysiological levels [13,14]. Further supporting a counterbalancing effect, mice overexpressing
desacyl ghrelin were shown to consume less food associated with a loss of body weight and fat mass
as well as reduced linear growth [15].
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Ghrelin is not only produced in X/A-like cells of the stomach [16], but also in pancreatic cells [17],
the intestine as well as to lesser extent in kidney, liver, spleen, heart, lung, gonads, skin and adipose
tissue [18]. Similarly, also GOAT is expressed in the stomach, pancreas, intestine, hypothalamus, ovary,
placenta, muscle, heart and adrenal glands and has been detected in the circulation as well [19–23]. Since the
lumen of the stomach provides the medium-chain fatty acids necessary for ghrelin’s acylation, the
main source of acylated ghrelin is assumed to be in the stomach [24]. The X/A-like cells are stimulated
through β1 adrenergic [25], GIP (gastric inhibitory polypeptide/glucose-dependent insulinotropic
peptide) [26], alpha transducin and gustducin and Tas1R3 receptor pathways [27], and inhibited via
somatostatin receptors [28,29].
Besides its stimulatory effect on food intake, in the last two decades ghrelin was shown to be
implicated in various functions giving rise to a pleiotropic mode of action [30] with stimulatory effects
on gastrointestinal motility, lipogenesis, blood glucose levels and inhibitory effects on blood pressure
and luteinizing hormone as well as follicle stimulating hormone [31]. It is also to note that ghrelin
exerts protective and/or therapeutic effects in rodents via the GHSR1a in different tissues including
the spinal cord [32], heart [33], kidney [34], pancreas [35–38], ulcerated oral mucosa [39,40], stomach
and duodenum [41–43] as well as colon [43–45].
Early on, it was described that ghrelin is regulated in a meal-dependent fashion with a
fasting/pre-prandial increase of gastric ghrelin and GOAT mRNA expression [23] resulting in increased
circulating ghrelin levels [46] and a decrease after the meal with lipids being especially potent to
reduce circulating ghrelin [47,48]. Interestingly, low gastric pH increases the release of desacyl ghrelin
from the stomach [49], probably to initiate the termination of food intake. Moreover, also chronic
alterations of body weight were shown to affect circulating ghrelin levels with a decrease observed
under conditions of overweight/obesity [50] and an increase in patients with cachexia [51] as well as
anorexia nervosa [52] as detailed below.
Peripheral ghrelin’s orexigenic effect is thought to be mediated centrally, namely after crossing
the blood-brain barrier via binding to its receptor located on NPY- and AgRP-expressing neurons in
the arcuate nucleus initiating the mTORC1/S6K1 (mechanistic target of rapamycin complex 1/p70
ribosomal protein kinase 1) pathway [53,54]. Moreover, ghrelin can also bind to vagal afferents that
signal to the brainstem to induce an orexigenic effect [55]. Consequently, ghrelin is a hallmark hormone
of the gut-brain axis and early on attracted attention as possible target in the treatment of conditions
where stimulation of food intake or weight gain is desired.
Patients suffering anorexia nervosa (AN) intentionally loss body weight by reducing food intake,
hyperactivity, self-induced vomiting and abuse of laxatives [56]. The body mass index (BMI) defined
as ≤17.5 kg/m2 and can reach life-threatening values under 12; consequently, the disease has a
high mortality between 5% and 20% [57]. The rising prevalence of eating disorders worldwide [58]
underlines the necessity to expand the knowledge about their pathophysiology. Recent studies give
rise to an important role for ghrelin in the pathophysiology and clinical course of AN.
Therefore, the present review will describe the alterations of ghrelin under conditions of AN and
ghrelin’s putative role as a drug candidate in the treatment of AN. Moreover, gaps in knowledge will
be addressed to stimulate future research.
2. Alteration of Ghrelin in Anorexia Nervosa
2.1. Basal Circulating Total Ghrelin Levels
In 2001 a significant difference between fasting plasma ghrelin levels in anorexic patients compared to
age-matched healthy controls was observed for the first time [52]. Ghrelin levels were elevated in AN
patients and reduced after therapeutically induced increase of BMI resulting in a negative correlation
between BMI and ghrelin [52]. Subsequent studies corroborated these findings [59,60], alterations also
observed in an animal model for anorexia nervosa, activity-based anorexia (ABA) [61,62]. Since ghrelin
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correlates positively with the extent of physical activity [63], hyperactivity is likely to play a role in the
elevation of ghrelin.
Additionally, a negative correlation between fasting ghrelin and insulin levels was observed [64].
Another study extended these findings by the observation of negative correlations between percent
body fat and serum cholesterase in AN as well as a positive correlation with serum amylase [65].
Interestingly, this study, using a self-developed radioimmunoassay, differentiated between anorexic
patients of the binge eating/purging type (AN-BP) and the restricted type (AN-R), showing
significantly higher fasting mean plasma levels of ghrelin in those with binge eating/purging behavior,
pointing towards an effect of bingeing and purging on ghrelin release/concentration [65], additionally
illustrating a positive correlation between frequencies of binge/purge cycles with plasma ghrelin
concentration [66]. In contrast, a negative correlation was observed between frequency and severity of
binge eating and purging behavior as measured by BULIT-R (bulimia test) total scores and ghrelin
concentrations, and lower plasma ghrelin concentrations in patients with AN-BP compared to those
suffering from AN-R [67]. These opposing results may result from different BMI values of included
subjects (13.7 ± 1.9 and 13.6 ± 1.5 in [65], 13.9 and 14.4 in [66] vs. 16.0 ± 2.4 in [67]). It has to be noted
that the results were obtained using different radioimmunoassays, self-developed [65] or commercially
purchased [67] possibly also contributing to the different levels observed. An additional study included
emergently hospitalized AN patients, showing higher ghrelin levels in those patients compared to
patients with AN-BP, AN-R and age-matched healthy female controls [68]. Further supporting a link
between purging and ghrelin, examinations using the Three-Factor Eating Questionnaire demonstrated
a positive correlation between ghrelin secretion during the cephalic phase and the tendency to lose
control over eating in AN [69].
Following up on these findings in studies comparing AN to normal weight controls, in 2003
a study compared AN patients with BMI-matched healthy subjects showing that AN patients had
doubled fasting and 24-h plasma ghrelin levels compared to constitutionally lean subjects [70], giving
rise to a role of ghrelin in the development or maintenance of AN. Another study even showed reduced
ghrelin levels in constitutionally lean subjects compared to normal weight controls, while ghrelin levels
in AN were increased [71]. Moreover, AN subjects also displayed higher ghrelin levels compared
to cancer patients developing cachexia [72]. The underlying mechanism responsible for this specific
up-regulation remains to be unraveled.
In 2005, a study examined ghrelin’s secretion in adolescents in detail, demonstrating that its
concentration is not only higher in AN but also its nadir as well as total area under the curve over
12 h of nocturnal sampling were elevated [73]; this period of time was chosen since ghrelin rises
physiologically under conditions of fasting such as during sleep, likely to stimulate subsequent food
intake [53]. In addition, secretory burst amplitude and burst mass were increased in AN resulting
in higher pulsatile and total ghrelin secretion [73]. Hereby, fasting ghrelin was related toGH burst
frequency with predictive value [73]. Nutritional markers such as BMI and body fat correlated with
nadir and post-glucose but not fasting ghrelin levels, whereas those were negatively related to fasting
insulin, insulin resistance, leptin, insulin-like growth factor (IGF-1) and HOMA-IR (homeostasis
model assessment of insulin resistance) [73,74]. Low levels of IGF-1 and insulin are likely related to
low energy and nutritional status in AN, since IGF-1 stimulates cell growth whereby an adequate
energy state is necessary [75], and insulin is responsible for anabolic processes suppressed due
to the lack of energy [76]. Furthermore, ghrelin was associated with total T3 (triiodothyronine)
and luteinizing hormone levels, but only nadir ghrelin independently predicted cortisol burst
frequency [73]. A different study observed this positive correlation between ghrelin and cortisol
only in female AN patients but not in female healthy controls [67], likely reflecting/contributing to the
stress component of the disease.
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2.2. Expression of Ghrelin
In immunohistological expression analyses of pituitary from healthy humans and anorexic subjects,
ghrelin was localized mainly in somatotrophs [77]. Controls showed only limited immunoreactivity,
whereas in the tissue of anorexic subjects immunoreactive cells were observed in nerve fibers and
Herring bodies of the posterior pituitary and pituitary stalk [77]. Moreover, in contrast to controls
ghrelin was additionally apparent in the anterior pituitary [77]. Higher central ghrelin signaling is
likely a compensatory mechanism to stimulate food intake and body weight gain in AN. It is important
to note that human data are lacking so far that describe the alterations of peripheral ghrelin expression
under conditions of AN.
ABA mice displayed an increase of preproghrelin mRNA-expressing cells of the stomach in proportion
to body weight loss [78]. Interestingly, hypothalamic preproghrelin mRNA expression was suppressed
in ABA mice [78], possibly pointing toward differential effects of central and peripheral ghrelin.
It has been reported that under conditions of food restriction in rats oxidative soleus type muscles
are more susceptible to circulating ghrelin compared to those of the glycolytic gastrocnemius type [79],
giving rise to a differential regulation of the ghrelin receptor due to anorexia, as was reported for e.g.,
hypothyroidism [80], a hypothesis to be further investigated.
2.3. Acyl and Desacyl Ghrelin
Subsequent studies investigated different forms of ghrelin showing that acyl ghrelin was significantly
increased in AN [81,82], likely to stimulate food intake in a compensatory fashion. It is to note
that another group described opposing results: an increase of desacyl ghrelin in AN and a negative
correlation with BMI, while acyl ghrelin was not/only slightly different without reaching significance
compared to healthy controls [83,84]. Adding more confusion, a study reported both, acyl and desacyl
ghrelin to be increased in patients with AN-R [85], whereas in constitutionally lean individuals acyl
ghrelin was observed to be decreased compared to normal weight controls [86]. These differences
might be due to different BMI values of the anorexic subjects studied (13.9 ± 1.0 [81] vs. 15.5 ± 2.6 [84]
vs. 13.4 ± 0.3 [85]) or population size (n = 5 [81] vs. n = 30 [84] vs. n = 10 [85]). Observing a circadian
profile, patients with AN-R showed higher total and acyl ghrelin levels compared to controls, whereas
subjects with AN-BP displayed decreased total and acyl ghrelin levels; moreover, the ratio of acyl/total
ghrelin was decreased in AN-BP [87,88]. The incongruence to findings mentioned before presenting
highest levels in AN-BP, followed by high levels in AN-R and the lowest levels of ghrelin in healthy
controls [65] could be explained by the different time points/period of time of blood sampling as well
as by the different BMI values (15.4 ± 1.4 and 15.2 ± 1.6 in [87] vs. 13.7 ± 1.9 and 13.6 ± 1.5 in [65]).
ELISA (enzyme-linked immunosorbent assay) examinations showed decreased auto-antibodies,
namely immune globulin G (IgG), IgM and IgA against acyl ghrelin and elevated levels of IgG
auto-antibodies against desacyl ghrelin in AN but not healthy subjects [89]. These auto-antibodies
against desacyl ghrelin were found mostly in immune complexes with desacyl ghrelin and were
negatively associated with plasma acyl and desacyl ghrelin, whereas acyl ghrelin IgM auto-antibodies
correlated with BMI [89]. It might be hypothesized that IgG against acyl ghrelin are reduced to allow
free acyl ghrelin to stimulate food intake, whereas desacyl ghrelin’s effect to lower food intake might
be inhibited by IgG bound to desacyl ghrelin leading to immune complexes in AN. In infants with
Prader-Willi syndrome elevated levels of desacyl ghrelin were observed, which have been implicated
in the anorexia observed at the beginning of the disease [90], giving rise to desacyl ghrelin’s inhibition
as a possible target in the treatment of anorexia (nervosa).
2.4. Nutrient-Related Alterations of Ghrelin
Physiologically, ghrelin is elevated before a meal and decreases after food consumption. However,
unlike in control subjects, acyl ghrelin levels in plasma from anorexic women did not decrease after
meal consumption [91]. Other studies observed a moderate (−25%) reduction of acyl ghrelin with
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a delayed onset (60–90 min after the meal) in subjects with AN following a mixed meal [64] or a
high-carbohydrate breakfast [92] which may represent a compensatory action to promote further
food intake. It is to note that especially fat intake predicted ghrelin values in plasma of patients with
AN [93], likely related to the need of fatty acids for ghrelin’s acylation in the stomach [24]. This is
further supported by the finding that consumption of medium-chain triglycerides elevates ghrelin
levels by activation of GOAT [94].
In contrast to food intake, modified sham feeding, where food is smelled and chewed but not
swallowed, resulted in an elevation of circulating ghrelin concentrations which was higher in AN
compared to age-matched healthy women [69], pointing towards an increased vagal tone in AN,
whose hyperactivity was described in adolescents suffering from AN before when investigating
cardiac functions [95].
Interestingly, in AN subjects the consumption of both favorite and unfavorite foods resulted in
the reduction of ghrelin levels while in healthy as well as former anorexic subjects eating of favorite
food further increased ghrelin levels [96]. To investigate underlying mechanisms, functional magnetic
resonance imaging can be used that indicated a positive relation between fasting acyl ghrelin and
activity in the right amygdala, hippocampus, insula, orbitofrontal cortex in response to high caloric
foods in normal weight subjects [97]. The association between acyl ghrelin and hippocampus activity
following a visual stimulus showing high caloric food was absent in AN but restored in AN patients
following weight recovery [97] indicating altered reward responsivity in AN.
During the oral glucose tolerance test (oGTT) subjects receive 75 mL of glucose solution which
induced a reduction of circulating ghrelin levels in healthy subjects [98]. An early study reported that
after an oGTT total ghrelin concentrations in plasma decreased both in AN (−49%) and healthy
age-matched controls (−57%); likewise, mean levels of plasma acyl ghrelin decreased in both
groups [81]. Interestingly, the type of AN had an impact on the kinetics of ghrelin changes with
a 58-% reduction of total ghrelin after 120 min in AN-BP, while in AN-R the 80-% decline was observed
180 min after the oGTT [99]. The mechanisms underlying this different time course warrant further
investigation. Another study did not observe a decrease of total ghrelin following glucose neither in
AN patients nor in healthy controls, while acyl ghrelin was significantly reduced [82] resulting in a
significantly reduced acyl/total ghrelin ratio [82,83,100]. Interestingly, early after the test (at 30 and
60 min) total [101], acyl and desacyl ghrelin [85] were increased.
In contrast to the ghrelin responses observed, less than one third of adolescent patients showed
an adequate reduction of GH levels following an oGTT [101]. Since ghrelin levels did not predict the
oGTT-induced response of GH [101] altered GHSR1a sensitivity might play a role, a hypothesis to be
further investigated.
2.5. Treatment-Related Alterations of Ghrelin
Weight regain of 14% in patients undergoing psychotherapy was associated with a 25-% reduction
of fasting plasma ghrelin levels [52], other studies even reported a normalization [102] or a decline of
plasma ghrelin below levels of control subjects [103]. Subsequent studies investigated these alterations
in more detail. Treatment encompassing cognitive behavioral therapy and nutritional therapy led to a
decrease of ghrelin levels in patients with AN emergently hospitalized as well as in AN-BP patients,
while in AN-R ghrelin levels even exceeded levels before beginning of treatment and control levels [68].
It is to note that AN-BP patients still had elevated ghrelin levels at the end of the treatment [68],
likely due to the fact that they did not reach the desired weight gain. Another study reported that
relative ghrelin changes did not differ before and after treatment, while absolute values of postprandial
ghrelin decreased from admission, partial weight gain and discharge, respectively (871.9, 597.0,
570.4 pg/mL) [104]. These changes were also observed over a long period of time (24 weeks) [105] and
could be reinstated after a short nutritional rehabilitation program [106].
Investigating the different forms of ghrelin, a study applying cognitive behavior therapy and
nutritional rehabilitation described a decrease of desacyl ghrelin resulting in an increased acyl/total
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ghrelin ratio [88]. This decrease of desacyl ghrelin was also observed in another study [107] and might
be accompanied by a reduction in anorexigenic signaling.
A study investigating acute meal-related changes observed that the postprandial decrease of
ghrelin was similar in anorexic patients and healthy controls reaching the nadir at 120 min [108].
However, in AN, ghrelin levels remained higher in comparison to healthy controls even after
therapy comprised of inpatient behavioral treatment involving operant techniques, nutritional
rehabilitation, psychotherapy, family therapy, and behavioral counseling, application of serotonin
reuptake inhibitors and sulpiride as well as nutritional therapy [108]. It is important to note
that other multimodal treatment approaches—here including cognitive behavioral psychotherapy
and programmed nutritional rehabilitation, combined with olanzapine or placebo—did not induce
alterations of ghrelin in AN patients [109], likely associated with the severity of the disease at the
beginning of the treatment (BMI 12.4 ± 1.7 vs. 16.3 ± 0.7).
3. Genetics Contributing to Altered Ghrelin Signaling in Anorexia Nervosa
Two studies in 2006 examined the association between several polymorphisms of the ghrelin gene
including Gln90Leu, Leu72Met, Arg51Gln described in obese and healthy humans before [110,111]
and the development of AN, observing no significant difference in the frequency of those gene variants
among anorexic and healthy subjects in Caucasian women or a mixed European population from Italy,
Spain, Germany, Slovenia, France, Austria and United Kingdom [112,113].
Subsequently, a significant correlation between the polymorphism Leu72Met, a region potentially
responsible for posttranslational processing, and the prevalence of AN-BP was documented [114]. This
polymorphism was predominantly detected in subjects with low BMI, fat mass and fasting respiratory
quotient [114]. In addition, regarding the Gln90Leu72 haplotype a significant transmission misbalance
in AN patients was detected, analyzing AN patients and both parents in a French population [114].
Regarding the recovery potential of anorexic patients, the TT genotype at 3056 T→C in the ghrelin
gene showed higher probability to achieve normal body weight [115]. An above-average prevalence
of the G/G genotype at the SNP (single nucleotide polymorphism) vs100096097 was discovered in
German anorexic subjects, resulting in a genetic variation in the GOAT enzyme [116]. Since GOAT
is reduced in patients with AN [21] and may thereby contribute to the reduced orexigenic drive in
these patients, this genetic alteration may well play a role in the pathophysiology of the disease. These
changes and a possible impact on treatment outcomes should be further evaluated in future studies.
4. Effects of Exogenous Ghrelin in Anorexia Nervosa
4.1. Effects of Ghrelin Administration
Due to the robust orexigenic effect of ghrelin, several studies investigated a potential therapeutic
use of the peptide. In ABA mice a GHSR1a antagonist, injected either acutely intracerebroventricularly
or chronically peripherally, inhibited food-anticipatory behavior but had no effect on total food
intake [62]. Intraperitoneal injection of ghrelin led to a blunted reduction of food intake under
conditions of ABA, preventing the development of ABA, nonetheless, animals still lost body
weight [117]. When combined with plasmatic anti-ghrelin IgG from obese, which is able to protect
ghrelin from degradation, thereby enhancing ghrelin’s orexigenic effects [118], ghrelin inhibited
physical activity during feeding and stimulated the activity after meal consumption resulting in
an elevated relation of consumed food to running distance during feeding time in ghrelin plus
IgG-receiving animals [117].
Modulations of ghrelin signaling were also tested in humans. Intravenous injection of ghrelin only
moderately increased GH, giving rise to a desensitization of the GHSR1a under conditions of AN [119].
However, ghrelin induced a regular increase of ACTH (adrenocorticotropic hormone) and cortisol
in AN [119], possibly pointing towards the mediation by different receptor subtypes. Another study
observed that ghrelin subjectively did not induce appetite but sleepiness in AN patients compared to
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constitutionally lean subjects [120], probably due to the ability of ghrelin to promote slow wave sleep
in humans [121]. Moreover, acyl ghrelin infused intravenously over 5 h increased glucose levels in
AN and even more in constitutionally lean subjects [122], possibly due to larger glycogen stores under
constitutionally lean conditions.
Chronic intravenous application (twice a day over 14 days) of ghrelin at a dose of 3 ug/kg body weight
resulted in improved epigastric discomfort and constipation in four of five patients, likely associated
with increased gastric motility [123]. Also hunger scores were increased leading to an increased energy
intake of 12% to 36% [123]. Similarly, in another study following the same administration protocol,
ghrelin suppressed upper abdominal fullness inducing stomach rumble and hunger sensation but not
constipation in five AN-R patients associated with an increase of daily energy intake by 20% [100].
Despite these encouraging results, these findings must be followed up in a larger sample under
controlled conditions.
4.2. Effects of Ghrelin-Related Products and Ghrelin Receptor Agonists
Not only ghrelin itself displayed beneficial effects in the course of AN, but also the ghrelin
enhancer rikkunshito, a traditional Japanese medicine, was shown in vitro to antagonize serotonin’s
action in POMC (pro-opiomelanocortin) neurons of the arcuate nucleus, whose release has been
described to be increased in AN [124]. Additionally, in cisplatin-treated rats rikkunshito was able to
prevent the reduction of plasma ghrelin levels by inhibiting ghrelin’s desacylation, resulting in an
augmented acyl/desacyl ghrelin ratio associated with a blunted decrease of food intake [125].
In humans, the effect of rikkunshito has been tested in chemotherapy-induced anorexia only,
leading to a reduction of nausea and emesis and a stimulation of appetite [126]. These findings
should be followed up in patients with AN as well. Very recently, a study investigated the effects of
relamorelin (subcutaneously daily over a period of four weeks), a ghrelin agonist, in an outpatient
cohort (n = 10–12/group) of AN showing a significant acceleration of gastric emptying as well as
a trend towards an increase of body weight (+0.9 kg vs. 0.3 kg in the control group, p < 0.07) [127].
Again, larger follow up studies are needed. These findings are surprising as ghrelin levels are already
elevated, and ghrelin resistance is suspected as described above. Nonetheless, the further increase of
ghrelin to supraphysiological levels might still be a promising approach to stimulate food intake in a
supportive manner.
5. Conclusions
In conclusion, ghrelin is the only known peripherally produced and centrally acting peptide
hormone that stimulates food intake and gastric motility. Additionally, ghrelin increases blood glucose
levels by reducing glucose-stimulated insulin secretion, insulin sensitivity and inducing glucagon
secretion [31]. In states of severe undernutrition and underweight such as AN, ghrelin is increased
compared to healthy controls, even if those are BMI-matched [70], which can be normalized through
weight gain and renutrition [102]. Genome-wide association studies demonstrated a relationship
between polymorphisms in the ghrelin gene [114] as well as in the gene of the enzyme acylating ghrelin,
GOAT [116] and the prevalence of AN [114], pointing towards a ghrelin-related genetic component of
AN. In AN not only central [77] and peripheral [78] ghrelin expression is increased, but also ghrelin
signaling and modulation are impaired as indicated by a delayed or absent postprandial decrease
of ghrelin [64,91], the inability to suppress GH secretion adequately after glucose digestion [101] or
the insufficiency of glucose elevation after exogenous ghrelin application [119], suggesting ghrelin
resistance in AN (Figure 1). Noteworthy, exogenous ghrelin (by raising ghrelin to supraphysiological
levels) or ghrelin receptor agonists still might be able to improve the course of AN by stimulating
appetite and reducing gastric discomfort leading to an increase of energy intake and body
weight [100,123,127]. Since these data are derived from small pilot studies, these effects should
be corroborated—or refuted—in larger clinical trials.
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